Rodman & Renshaw Initiates Coverage On Mural Oncology with Buy Rating, Announces Price Target of $15
Portfolio Pulse from Benzinga Newsdesk
Rodman & Renshaw initiates coverage on Mural Oncology (NASDAQ:MURA) with a Buy rating and sets a price target of $15.
June 28, 2024 | 4:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rodman & Renshaw has initiated coverage on Mural Oncology with a Buy rating and a price target of $15, indicating positive analyst sentiment.
The initiation of coverage with a Buy rating and a price target of $15 by Rodman & Renshaw is likely to boost investor confidence in Mural Oncology, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100